<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">APREPITANT</span><br/>(a-pre'pi-tant)<br/><span class="topboxtradename">Emend<br/></span><b>Classifications:</b> <span class="classification">gastrointestinal agent</span>; <span class="classification">antiemetic</span>; <span class="classification">substance p neurokinin 1 (nk-1) receptor antagonist</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>80 mg, 125 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Aprepitant is a selective substance P/neurokinin 1 (NK<sub>1</sub>) receptor antagonist. Substance P and the NK-1 receptors are present in areas in the brain that control the emetic reflex.
         Aprepitant crosses the bloodbrain barrier and occupies brain NK<sub>1</sub> receptors. Peripheral blockade by NK<sub>1</sub> receptor antagonists at receptors located in the GI is an additional hypothesized mechanism of action.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Aprepitant augments the antiemetic activity of the 5-HT<sub>3</sub>-receptor antagonist, ondansetron, and inhibits both the acute and delayed phases of emesis induced by chemotherapy agents.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention of acute and delayed nausea and vomiting associated with moderate to severe emetogenic chemotherapy</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to aprepitant; concurrent use of pimozide; children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Chemotherapeutic agents metabolized through CYP3A4; severe hepatic impairment; severe renal impairment without dialysis; pregnancy
         (category B).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Chemotherapy-Induced Nausea &amp; Vomiting</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 125 mg 1 h prior to chemotherapy, then 80 mg qam for the next 2 d in conjunction with other antiemetics<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Ensure that capsule is swallowed whole with a full glass of water. Do not crush or sprinkle the contents of the capsule.</li>
<li>Give 1 h before start of chemotherapy.</li>
<li>Store at 20°25° C (68°77° F). Keep the desiccant in the original bottle.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>
<span class="speceff-common">Fatigue,</span> asthenia, malaise, dehydration, fever. <span class="typehead">CNS:</span> Dizziness, insomnia, headache, peripheral neuropathy, sensory neuropathy, anxiety, confusion, depression. <span class="typehead">GI:</span>
<span class="speceff-common">Constipation, diarrhea, anorexia, nausea, hiccups,</span> abdominal pain, gastritis, gastroesophageal reflux, abnormal or impaired taste (dysgeusia), dyspepsia, dysphagia, flatulence,
      hypersalivation, increased taste disturbance, increased AST and ALT. <span class="typehead">Hematologic:</span> Neutropenia, anemia. <span class="typehead">Musculoskeletal:</span> Pain, myalgia. <span class="typehead">Respiratory:</span> Cough, dyspnea, upper or lower respiratory infection, pneumonitis, respiratory insufficiency. <span class="typehead">Special Senses:</span> Tinnitus. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Increased risk of cardiovascular toxicity with <b>dofetilide,</b>
<b>pimozide;</b> may decrease <b>warfarin</b> concentrations and INR; may decrease levels and effectiveness of <span class="classification">oral contraceptives</span>; <b>carbamazepine,</b>
<b>griseofulvin,</b>
<b>modafinil,</b>
<b>rifabutin,</b>
<b>rifapentine,</b>
<b>phenobarbital,</b>
<b>primidone</b> may decrease antiemetic efficacy; may increase levels of <b>dexamethasone.</b> Because aprepitant is a substrate of CYP3A4, many additional drug interactions are theoretically possible. <span class="typehead">Food:</span>
<b>Grapefruit juice</b> may decrease effectiveness of aprepitant. <span class="typehead">Herbal:</span>
<b>St. John's wort</b> may decrease effectiveness of aprepitant. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 6065% of oral dose reaches systemic circulation. <span class="typehead">Peak:</span> 4 h. <span class="typehead">Duration:</span> 95% protein bound; readily crosses the bloodbrain barrier. <span class="typehead">Metabolism:</span> Metabolized in liver by CYP3A4. <span class="typehead">Elimination:</span>  Not renally excreted. <span class="typehead">Half-Life:</span> 912 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor cardiac status especially with preexisting CV disease or concurrent use of any CYP3A4 substrate drug (e.g., ketoconazole,
            itraconazole, nefazodone, troleandomycin, clarithromycin).
         </li>
<li>Lab tests: Monitor PT/INR 710 d after 3-d regimen with concurrent warfarin use; monitor phenytoin level with concurrent
            use; monitor serum electrolytes, UA, and CBC.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately to physician any of the following: skin rash; difficulty breathing or shortness of breath; rapid, slow,
            or irregular heartbeat; changes in BP; dizziness or confusion; unexplained sharp or severe pain in leg or stomach; rectal
            bleeding. Inform physician of all other drugs or herbal products you are using. Do not take new drugs (prescription, OTC,
            herbal) without first consulting physician.
         </li>
<li>Use barrier contraception in addition to oral contraceptives while taking drug.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>